# Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

> **NCT06069843** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 15 (actual)

## Conditions studied

- Depression
- Mild Cognitive Impairment

## Interventions

- **DRUG:** IV Ketamine

## Key facts

- **NCT ID:** NCT06069843
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06069843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06069843, "Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06069843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*